Literature DB >> 19499454

Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy.

V A Cardenas1, D J Meyerhoff, C Studholme, J Kornak, J Rothlind, H Lampiris, J Neuhaus, R M Grant, L L Chao, D Truran, M W Weiner.   

Abstract

Treatment with antiretroviral therapy (ART) has greatly reduced the incidence of dementia. The goal of this longitudinal study was to determine if there are ongoing macrostructural brain changes in human immunodeficiency virus-positive (HIV + ) individuals treated with ART. To quantify brain structure, three-dimensional T1-weighted magnetic resonance imaging (MRI) scans were performed at baseline and again after 24 months in 39 HIV+ patients on ART and 30 HIV- controls. Longitudinal changes in brain volume were measured using tissue segmentation within regions of interest and deformation morphometry. Measured by tissue segmentation, HIV+ patients on ART had significantly (all P<.05) greater rates of white matter volume loss than HIV- control individuals. Compared with controls, the subgroup of HIV+ individuals on ART with viral suppression also had significantly greater rates of white matter volume loss. Deformation morphometry confirmed these results with more specific spatial localization. Deformation morphometry also detected greater rates of gray matter and white matter loss in the subgroup of HIV+ individuals with detectable viral loads. These results provide evidence of ongoing brain volume loss in HIV+ individuals on stable ART, possibly suggesting ongoing cerebral injury. The presence of continuing injury raises the possibility that HIV+ individuals-even in the presence of viral suppression in the periphery-are at greater risk for future cognitive impairments and dementia and possibly faster cognitive decline. Therefore, HIV+ individuals on ART should be monitored for cognitive decline, and treatments that reduce ongoing neurological injury should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499454      PMCID: PMC2889153          DOI: 10.1080/13550280902973960

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  41 in total

1.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

2.  Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment.

Authors:  V Di Sclafani; R D Mackay; D J Meyerhoff; D Norman; M W Weiner; G Fein
Journal:  J Int Neuropsychol Soc       Date:  1997-05       Impact factor: 2.892

3.  Altered brain tissue composition in heavy marijuana users.

Authors:  John A Matochik; Dana A Eldreth; Jean-Lud Cadet; Karen I Bolla
Journal:  Drug Alcohol Depend       Date:  2005-01-07       Impact factor: 4.492

4.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

Review 5.  Neuroimaging in human immunodeficiency virus infection.

Authors:  Karen A Tucker; Kevin R Robertson; Weili Lin; J Keith Smith; Hongyu An; Yasheng Chen; Stephen R Aylward; Colin D Hall
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

6.  MR volumetry during acute alcohol withdrawal and abstinence: a descriptive study.

Authors:  Ingrid Agartz; Svante Brag; Johan Franck; Anders Hammarberg; Gaku Okugawa; Katarina Svinhufvud; Hans Bergman
Journal:  Alcohol Alcohol       Date:  2003 Jan-Feb       Impact factor: 2.826

7.  Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis.

Authors:  G J Dal Pan; J H McArthur; E Aylward; O A Selnes; T E Nance-Sproson; A J Kumar; E D Mellits; J C McArthur
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

8.  Brain macrostructural and microstructural abnormalities in cocaine dependence.

Authors:  Kelvin O Lim; Jeffrey R Wozniak; Bryon A Mueller; Daniel T Franc; Sheila M Specker; Craig P Rodriguez; Amy B Silverman; John P Rotrosen
Journal:  Drug Alcohol Depend       Date:  2007-09-29       Impact factor: 4.492

9.  Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.

Authors:  Anne C Roc; Beau M Ances; Sanjeev Chawla; Marc Korczykowski; Ronald L Wolf; Dennis L Kolson; John A Detre; Harish Poptani
Journal:  Arch Neurol       Date:  2007-07-09

Review 10.  Effects of alcohol and HIV infection on the central nervous system.

Authors:  D J Meyerhoff
Journal:  Alcohol Res Health       Date:  2001
View more
  84 in total

Review 1.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Independent effects of HIV, aging, and HAART on brain volumetric measures.

Authors:  Beau M Ances; Mario Ortega; Florin Vaida; Jodi Heaps; Robert Paul
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

3.  Effects of HIV and early life stress on amygdala morphometry and neurocognitive function.

Authors:  Uraina S Clark; Ronald A Cohen; Lawrence H Sweet; Assawin Gongvatana; Kathryn N Devlin; George N Hana; Michelle L Westbrook; Richard C Mulligan; Beth A Jerskey; Tara L White; Bradford Navia; Karen T Tashima
Journal:  J Int Neuropsychol Soc       Date:  2012-05-24       Impact factor: 2.892

Review 4.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

5.  Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.

Authors:  Josué Pérez-Santiago; Rachel D Schrier; Michelli F de Oliveira; Sara Gianella; Susanna R Var; Tyler R C Day; Miguel Ramirez-Gaona; Jesse D Suben; Ben Murrell; Marta Massanella; Mariana Cherner; Davey M Smith; Ronald J Ellis; Scott L Letendre; Sanjay R Mehta
Journal:  J Neurovirol       Date:  2015-10-01       Impact factor: 2.643

6.  A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects.

Authors:  Veera Venkata Ratnam Bandaru; Michelle M Mielke; Ned Sacktor; Justin C McArthur; Igor Grant; Scott Letendre; Linda Chang; Valerie Wojna; Carlos Pardo; Peter Calabresi; Sody Munsaka; Norman J Haughey
Journal:  Neurology       Date:  2013-09-11       Impact factor: 9.910

7.  Brief Report: Low-Dose Hydrocortisone Has Acute Enhancing Effects on Verbal Learning in HIV-Infected Men.

Authors:  Leah H Rubin; K Luan Phan; Sheila M Keating; Kathleen M Weber; Pauline M Maki
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

Review 8.  A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV.

Authors:  Norman J Haughey; Xiaomao Zhu; Veera Venkata Ratnam Bandaru
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-08       Impact factor: 4.147

9.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

10.  Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy.

Authors:  Assawin Gongvatana; Jaroslaw Harezlak; Steven Buchthal; Eric Daar; Giovanni Schifitto; Thomas Campbell; Michael Taylor; Elyse Singer; Jeffrey Algers; Jianhui Zhong; Mark Brown; Deborah McMahon; Yuen T So; Deming Mi; Robert Heaton; Kevin Robertson; Constantin Yiannoutsos; Ronald A Cohen; Bradford Navia
Journal:  J Neurovirol       Date:  2013-04-24       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.